In an editorial paper published in Oncotarget titled, "DDX41 and its unique contribution to myeloid leukemogenesis," researcher Hirotaka Matsui from the National Cancer Center Hospital in Tokyo, Japan, and Kumamoto University ...
Jul 22, 2024
0
22
Relapsed/refractory acute myeloid leukemia (AML), a blood cancer, has an extremely poor prognosis because of resistance to anti-cancer drugs and frailty of the patient's organ functions. A type of anti-tumor immunotherapy ...
Jul 18, 2024
0
27
Ophthalmologic manifestations of acute leukemia are heterogeneous and detectable at initial presentation or relapse, according to a study published online July 10 in the Annals of Hematology.
Jul 17, 2024
0
28
The protein STAT3 helps the immune system to recognize leukemic cells. This interaction, which is important for future immunotherapies, is now understood in detail thanks to a study at the Karl Landsteiner University of Health ...
Jul 16, 2024
0
31
Researchers from King's College have led research that has resulted in the publication of first-of-their-kind guidelines that seek to standardize how clinicians measure the immune response of patients who have myelodysplastic ...
Jul 12, 2024
0
37
A new editorial paper titled "Genomics has more to reveal" has been published in Oncotarget.
Jul 2, 2024
0
37
Researchers show for the first time that engineered human plasma B cells can be used to treat a disease—specifically leukemia—in a humanized animal model. The results mark a key step in the realization of ePCs as therapies ...
Jul 2, 2024
0
52
Researchers from the University of Missouri School of Medicine found that a targeted gene therapy may make acute myeloid leukemia (AML) more sensitive to chemotherapy, while also protecting the heart against toxicity often ...
Jun 27, 2024
0
293
Peter Mac clinicians have described how a young patient with a rare, aggressive and only recently described form of acute myeloid leukemia (AML) has responded to genomically-guided targeted therapy.
Jun 27, 2024
0
220
For patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplantation, posttransplant cyclophosphamide (PTCy) graft-versus-host-disease (GVHD) prophylaxis yields comparable relapse incidence (RI) ...
Jun 24, 2024
0
41
